Last reviewed: April 2026
AI-powered biotechnology platform that accelerates research, drug development.
Grail (Illumina) is an AI-powered biotechnology platform that accelerates research, drug development, and therapeutic innovation. It is designed for clinical labs, pathologists, geneticists across the biotechnology and life sciences sector. Founded in 2010, the company is recognized for its fda-cleared tests and clinical accuracy.
Grail (Illumina) is best suited for clinical labs, pathologists, geneticists. $949/test pricing for biotech teams.
Official website: Grail (Illumina)
Compare Grail (Illumina) with other platforms
The platform is designed to address the specific challenges faced by Biotech organizations. Key users include Clinical labs, Pathologists, Geneticists who rely on the platform for multi-cancer screening, early detection ai, blood-based diagnostics. In the rapidly evolving Biotech landscape, Grail (Illumina) stands out by combining genomic diagnostics capabilities with industry-specific features that address the unique challenges of multi-cancer screening, early detection ai, blood-based diagnostics. The platform enables Clinical labs and Pathologists to transition from manual, error-prone processes to automated, data-driven workflows that deliver consistent results at scale. Compared to alternatives in the genomic diagnostics space, Grail (Illumina) differentiates itself through its focus on Biotech use cases, and $949/test that accommodates organizations at different stages of their AI adoption journey.
Before adopting Grail (Illumina) or any Genomic Diagnostics solution for your biotech workflows, it is important to assess how the platform fits your specific requirements. Start by mapping your highest-priority pain points — whether that is reducing manual tasks, improving data accuracy, scaling customer interactions, or accelerating time to insight. Grail (Illumina) positions itself as a Genomic Diagnostics solution, having been in the market since 2010, so evaluate whether its feature set directly addresses those pain points rather than relying on feature-list comparisons alone.
Request a live demo or proof-of-concept trial before committing to an annual contract. During the trial, measure concrete outcomes: task completion time, error rates, user adoption speed, and integration friction with your existing stack. Compare these metrics against at least two alternative vendors in the Genomic Diagnostics space to establish a meaningful benchmark. Grail (Illumina) uses a $949/test pricing model — make sure you understand the total cost of ownership including implementation, training, and any per-seat or usage-based fees.
Confirm deployment options meet your IT and compliance requirements. Verify what compliance certifications and data-handling guarantees the vendor provides, especially for regulated biotech environments. Also ask about the vendor's SLA for uptime, support response times, and the data export process should you decide to switch providers in the future.
Grail (Illumina) is a Genomic Diagnostics platform designed for biotech organizations. AI-powered biotechnology platform that accelerates research, drug development.
Grail (Illumina) scores 9.2/10 on AI Scanner's independent evaluation. The score reflects performance (30%), usability (25%), pricing value (25%), and versatility (20%). Scores are updated monthly based on product changes, user feedback, and competitive benchmarking across Genomic Diagnostics tools. Read our full scoring methodology.
The top alternative to Grail (Illumina) on AI Scanner is Sophia Genetics with a score of 9/10. Other alternatives include Aria Diagnostics (SOPHiA GENETICS), Veracyte, Variantyx. Compare all alternatives.
Grail (Illumina) is designed for enterprise organizations. Its $949/test pricing model scales with team size and usage requirements. We recommend running a pilot with your actual workflows before committing to a full deployment.
Grail (Illumina) uses a $949/test pricing model. For the most accurate pricing, request a custom quote directly from the vendor. Pricing may vary based on deployment scale, feature tier, and contract length. Always factor in implementation and training costs when comparing total cost of ownership against competitors.
How We Score: AI Scanner evaluates platforms across four dimensions - Performance (30%), Usability (25%), Pricing Value (25%), and Versatility (20%). Scores are updated monthly. Read our full methodology.